1
Magnetic Marker Monitoring of Furosemide-containing Gastroretentive Formulation in Healthy Male Subjects (Fasting and Fed Conditions)
Condition(s):Gastroretentive Drug Formulation of Furosemide; OedemaLast Updated:December 12, 2013Completed
Ferrosoferric Oxide: 99 Clinical Trials, Page 1 of 10
Hide Studies Not Open or Pending
2
Virtual Histology of the Bladder Wall for Bladder Cancer Staging
Condition(s):Urinary Bladder NeoplasmsLast Updated:September 26, 2023Recruiting
3
MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy
Condition(s):Adult Brain GlioblastomaLast Updated:May 16, 2017Completed
4
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Condition(s):Liver Neoplasms; Hepatic Cirrhosis; Hepatic Carcinoma; Liver Cancer; Liver Metastases; Liver Carcinoma; Hepatocellular Carcinoma; Hepatocellular Cancer; Hepatic AtrophyLast Updated:February 21, 2023Active, not recruiting
5
MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal Cancer
Condition(s):Esophageal CancerLast Updated:May 13, 2016Withdrawn
6
Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study
Condition(s):Papillary Carcinoma of Thyroid Gland; Metastatic Medullary Thyroid Cancer; Follicular Thyroid Cancer Lymph Node MetastasisLast Updated:June 6, 2017Completed
7
In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging
Condition(s):Multiple SclerosisLast Updated:August 24, 2023Completed
8
Ferumoxytol – Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI
Condition(s):Head and Neck CancerLast Updated:September 21, 2021Terminated
9
Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging
Condition(s):Cancer of Lymph NodeLast Updated:October 19, 2020Completed
10
Novel Imaging Markers in SPMS
Condition(s):Secondary Progressive Multiple Sclerosis; Multiple Sclerosis, Secondary Progressive; Multiple SclerosisLast Updated:September 26, 2023Completed